Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
Preetesh Jain(The University of Texas MD Anderson Cancer Center), Michael Wang(The University of Texas MD Anderson Cancer Center), Francisco Vega(The University of Texas MD Anderson Cancer Center), David Santos(The University of Texas MD Anderson Cancer Center), Graciela M. Nogueras‐González(The University of Texas MD Anderson Cancer Center), Lucy Navsaria(The University of Texas MD Anderson Cancer Center), Hun Ju Lee(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Cezar Iliescu(The University of Texas MD Anderson Cancer Center), Selvi Thirumurthi(The University of Texas MD Anderson Cancer Center), Nathan Fowler(The University of Texas MD Anderson Cancer Center), Yixin Yao(The University of Texas MD Anderson Cancer Center), Linghua Wang, Chi Young Ok(The University of Texas MD Anderson Cancer Center), Shuangtao Zhao(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Omar Moghrabi(The University of Texas MD Anderson Cancer Center), Lei Feng(Shandong Tumor Hospital), Michelle Avellaneda(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(CancerCare Manitoba), Holly A. Hill(The University of Texas MD Anderson Cancer Center), Yang Liu(The University of Texas MD Anderson Cancer Center), Guofan Xu(The University of Texas MD Anderson Cancer Center), L. Jeffrey Medeiros(The University of Texas MD Anderson Cancer Center), Maria Badillo(The University of Texas MD Anderson Cancer Center), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center)
Cited by 82
Related Papers
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
|Science|2021|876
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829